Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.59 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.52 |
| ▸ | ABAT | P80404 | 1/20 | 0.50 |
| ▸ | F11 | P03951 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112119 | 0.97 | — | — | |
| Methane SCHEMBL10520385 | 0.94 | TAAR1 (0.59) | TAAR1HTR2AHRH3IDO1LOXL2 | |
| Iodide SCHEMBL28970937 | 0.94 | TAAR1 (0.59) | TAAR1HTR2AHRH3IDO1LOXL2 | |
| Bromide SCHEMBL29023877 | 0.94 | TAAR1 (0.59) | TAAR1HTR2AHRH3IDO1LOXL2 | |
| Hydrochloric Acid SCHEMBL28560181 | 0.92 | TAAR1 (0.56) | TAAR1HTR2AHRH3IDO1LOXL2 | |
| SCHEMBL5828443 | 0.89 | HRH3 (0.74) | TAAR1HTR2AHRH3IDO1LOXL2 | |
| SCHEMBL28384280 | 0.87 | TAAR1 (0.52) | TAAR1HTR2AHRH3IDO1LOXL2 | |
| Hydrochloric Acid SCHEMBL921495 | 0.86 | ST14 (0.65) | TAAR1HTR2AHRH3IDO1MAPT | |
| SCHEMBL17967545 | 0.85 | MAOB (0.53) | TAAR1HTR2AHRH3IDO1LOXL2 | |
| Hydrochloric Acid SCHEMBL3168189 | 0.84 | HRH3 (0.73) | TAAR1HRH3LOXL2ABATF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876375-A | Preparation method of p-bromobenzylamine hydrochloride as intermediate for synthesizing protein degradation agent 1 | 苏州莱克施德药业有限公司 | 2021-06-01 | — | — | CN | claimed |
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| CN-105294458-B | A kind of anti-tumor small molecular compound and its preparation method and application | 中国人民解放军第四军医大学 | 2017-07-11 | — | — | CN | claimed |
| CN-105294458-A | Antineoplastic small molecular compound and preparation method and application thereof | FOURTH MILITARY MEDICAL UNIV | 2016-02-03 | — | — | CN | claimed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | claimed |
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| CN-121148922-A | Aluminum electrolytic capacitor with good stability and preparation method thereof | 益阳市安兴电子有限公司 | 2025-12-16 | — | — | CN | disclosed |
| US-20250353853-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-11-20 | — | — | US | disclosed |
| US-12453734-B2 | Modulators of rho-associated protein kinase | REDX PHARMA LIMITED (GB) | 2025-10-28 | — | — | US | disclosed |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | AURIGENE DISCOVERY TECH LTD (IN) | 2025-07-29 | — | — | US | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-0539086-A2 | Condensed pyrimidine derivatives and their use as angiotensine II antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| EP-0495091-A4 | AICA RIBOSIDE ANALOGS | — | 1993-01-07 | — | — | EP | disclosed |
| US-5149699-A | Substituted pyridopyrimidines useful as antgiotensin II antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-22 | — | — | US | disclosed |
| EP-0495091-A1 | AICA RIBOSIDE ANALOGS | GENSIA, INC. (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1992002214-A1 | AICA RIBOSIDE ANALOGS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002213-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| EP-0078703-A2 | New tagged pyroglu-l-phe-l-arg derivatives, substrates and assays for kallikrein | UNIVERSITY OF MIAMI (US) | 1983-05-11 | — | — | EP | disclosed |
| US-4329417-A | OXIDIZERS AND QUATERNARY AMMONIUM SALTS, PHOSPHONIUM SALTS OR SULFONIUM SALTS | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | HTR2A 3362/4885HRH3 3864/4885CA2 495/4885 |
| US-12453734-B2 | Modulators of rho-associated protein kinase | ROCK2, ROCK1, RHOA | HTR2A 3411/4885HRH3 2332/4885CA2 856/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | HTR2A 3424/4885HRH3 1994/4885CA2 2940/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | HTR2A 1844/4885HRH3 1811/4885CA2 1488/4885 |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | SMARCC1, SMARCC2, SMARCA2 | HTR2A 200/4885HRH3 1541/4885CA2 3193/4885 |
| US-20250353853-A1 | FLAVIVIRUS INHIBITORS | SPINT2, EIF2AK2, DDX5 | HTR2A 3334/4885HRH3 3297/4885CA2 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.